Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population-based cohort study

ObjectiveThis population-based study examined the association between baseline uric acid (UA) and prostate cancer (PCa)-related mortality amongst PCa patients receiving androgen deprivation therapy (ADT). MethodsAdults with PCa who received ADT in Hong Kong between December 1999 and March 2021 were identified. Patients with missing baseline UA were excluded. Patients were followed up until September 2021. The outcome was PCa-related mortality. ResultsAltogether, 4126 patients (median follow-up 3.1[interquartile range 1.4-6.0] years) were included. A J-shaped association was observed between baseline UA level and PCa-related mortality risk, with a direct association in those with mean(0.401 mmol/L) or above-mean baseline UA levels (hazard ratio (HR) per standard deviation-increase 1.35 [95% confidence interval 1.21,1.51], p < 0.001), and an inverse association in those with below-mean baseline UA levels (HR 0.78[0.67,0.92], p = 0.003). The former remained significant on competing risk regression, but not the latter. ConclusionsA J-shaped relationship between baseline UA level and PCa-related mortality risk was identified. This study was mainly limited by potential unmeasured and residual confounders. Further validation studies are warranted.

Automated summary

This population-based study investigated the association between baseline uric acid (UA) levels and prostate cancer (PCa)-related mortality in PCa patients undergoing androgen deprivation therapy (ADT). The results revealed a J-shaped relationship, with a direct association in patients with above-average UA levels and an inverse association in patients with below-average UA levels.